Johnson & Johnson arm halts R & D on Hepatitis C drug
Instead, the company will focus on a cure for chronic hepatitis B, an inflammation of the liver caused by a different virus.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Hepatitis | Hepatitis B | Hepatitis C | Liver | Pharmaceuticals | Urology & Nephrology